These findings are consistent with prior meta-analytic evidence confirming silymarin’s hepatoprotective effects in NAFLD, including significant improvements in ALT and AST levels, reductions in hepatic steatosis, and decreased liver stiffness (24). The gene discussed is GPT; the disease is Hepatic steatosis.